{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:30:37Z","timestamp":1783344637806,"version":"3.54.6"},"reference-count":66,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["17\/98\/01"],"award-info":[{"award-number":["17\/98\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"Background<\/jats:title>\nHidradenitis suppurativa is a chronic inflammatory skin disease characterised by recurrent inflammatory lesions and skin tunnels in flexural sites such as the axilla. Deroofing of skin tunnels and laser treatment are standard hidradenitis suppurativa interventions in some countries but not yet introduced in the United Kingdom.<\/jats:p>\n<\/jats:sec>\nObjective<\/jats:title>\nTo understand current hidradenitis suppurativa management pathways and what influences treatment choices to inform the design of future randomised controlled trials.<\/jats:p>\n<\/jats:sec>\nDesign<\/jats:title>\nProspective 12-month observational cohort study, including five treatment options, with nested qualitative interviews and an end-of-study consensus workshop.<\/jats:p>\n<\/jats:sec>\nSetting<\/jats:title>\nTen United Kingdom hospitals with recruitment led by dermatology and plastic surgery departments.<\/jats:p>\n<\/jats:sec>\nParticipants<\/jats:title>\nAdults with active hidradenitis suppurativa of any severity not adequately controlled by current treatment.<\/jats:p>\n<\/jats:sec>\nInterventions<\/jats:title>\nOral doxycycline 200 mg once daily; oral clindamycin and rifampicin, both 300 mg twice daily for 10 weeks initially; laser treatment targeting the hair follicle (neodymium-doped yttrium aluminium garnet or alexandrite); deroofing; and conventional surgery.<\/jats:p>\n<\/jats:sec>\nMain outcome measures<\/jats:title>\nPrimary outcome was the proportion of participants who are eligible, and hypothetically willing, to use the different treatment options. Secondary outcomes included proportion of participants choosing each of the study interventions, with reasons for their choices; proportion of participants who switched treatments; treatment fidelity; loss to follow-up rates over 12 months; and efficacy outcome estimates to inform outcome measure instrument responsiveness.<\/jats:p>\n<\/jats:sec>\nResults<\/jats:title>\nBetween February 2020 and July 2021, 151 participants were recruited, with two pauses due to the COVID-19 pandemic. Follow-up rates were 89% and 83% after 3 and 6 months, decreasing to 70% and 44% at 9 and 12 months, respectively, because pandemic recruitment delays prevented all participants reaching their final review. Baseline demographics included an average age of 36 years, 81% female, 20% black, Asian or Caribbean, 64% current or ex-smokers and 86% with a raised body mass index. Some 69% had moderate disease, 19% severe disease and 13% mild disease.<\/jats:p>\nRegarding the study\u2019s primary outcome, laser treatment was the intervention with the highest proportion (69%) of participants who were eligible and hypothetically willing to receive treatment, followed by deroofing (58%), conventional surgery (54%), the combination of oral clindamycin and rifampicin (44%) and doxycycline (37%). Considering participant willingness in isolation, laser was ranked first choice by the greatest proportion (41%) of participants. The cohort study and qualitative study demonstrated that participant willingness to receive treatment was strongly influenced by their clinician.<\/jats:p>\nFidelity to oral doxycycline was only 52% after 3 months due to lack of effectiveness, participant preference and adverse effects. Delays receiving procedural interventions were common, with only 43% and 26% of participants commencing laser therapy and deroofing, respectively, after 3 months. Treatment switching was uncommon and there were no serious adverse events.<\/jats:p>\nDaily pain score text messages were initiated in 110 participants. Daily responses reduced over time with greatest concordance during the first 14 days.<\/jats:p>\n<\/jats:sec>\nLimitations<\/jats:title>\nIt was not possible to characterise conventional surgery due to a low number of participants.<\/jats:p>\n<\/jats:sec>\nConclusion<\/jats:title>\nThe Treatment of Hidradenitis Suppurativa Evaluation Study established deroofing and laser treatment for hidradenitis suppurativa in the United Kingdom and developed a network of 10 sites for subsequent hidradenitis suppurativa randomised controlled trials.<\/jats:p>\n<\/jats:sec>\nFuture work<\/jats:title>\nThe consensus workshop prioritised laser treatment and deroofing as interventions for future randomised controlled trials, in some cases combined with drug treatment.<\/jats:p>\n<\/jats:sec>\nTrial registration<\/jats:title>\nThis trial is registered as ISRCTN69985145.<\/jats:p>\n<\/jats:sec>\nFunding<\/jats:title>\nThis award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 12\/35\/64) and is published in full in Health Technology Assessment<\/jats:italic>; Vol. 27, No. 30. See the NIHR Funding and Awards website for further award information.<\/jats:p>\n<\/jats:sec>","DOI":"10.3310\/hwnm2189","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T12:33:42Z","timestamp":1703594022000},"page":"1-107","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of Hidradenitis Suppurativa Evaluation Study: the THESEUS prospective cohort study"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1142","authenticated-orcid":true,"given":"John R","family":"Ingram","sequence":"first","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-2415","authenticated-orcid":true,"given":"Janine","family":"Bates","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5235-6517","authenticated-orcid":true,"given":"Rebecca","family":"Cannings-John","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5271-9170","authenticated-orcid":true,"given":"Fiona","family":"Collier","sequence":"additional","affiliation":[{"name":"NHS Forth Valley, Stirling, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5285-4954","authenticated-orcid":true,"given":"Angela","family":"Gibbons","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0462-7789","authenticated-orcid":true,"given":"Ceri","family":"Harris","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5268-8631","authenticated-orcid":true,"given":"Kerenza","family":"Hood","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4157-7394","authenticated-orcid":true,"given":"Laura","family":"Howells","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6120-8433","authenticated-orcid":true,"given":"Rachel","family":"Howes","sequence":"additional","affiliation":[{"name":"Burns and Plastic Surgery, Stoke Mandeville Hospital, Aylesbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-0274","authenticated-orcid":true,"given":"Paul","family":"Leighton","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5512-1745","authenticated-orcid":true,"given":"Muhammad","family":"Riaz","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-5026","authenticated-orcid":true,"given":"Jeremy","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Burns and Plastic Surgery, Stoke Mandeville Hospital, Aylesbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-3667","authenticated-orcid":true,"given":"Helen","family":"Stanton","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-7465","authenticated-orcid":true,"given":"Kim S","family":"Thomas","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-2786","authenticated-orcid":true,"given":"Emma","family":"Thomas-Jones","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2023,12]]},"reference":[{"key":"key2023122618012400_ref1-bib1","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1111\/bjd.16603","article-title":"Profound consequences of hidradenitis suppurativa: a review","volume":"183","author":"Matusiak","year":"2020","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref2-bib2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","article-title":"Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project","volume":"82","author":"Garg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"key2023122618012400_ref3-bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.7861\/clinmedicine.16-1-70","article-title":"Hidradenitis suppurativa: an update","volume":"16","author":"Ingram","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"key2023122618012400_ref4-bib4","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1111\/bjd.16515","article-title":"Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa","volume":"178","author":"Ingram","year":"2018","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref5-bib5","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/bjd.19435","article-title":"The epidemiology of hidradenitis suppurativa","volume":"183","author":"Ingram","year":"2020","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref6-bib6","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/bjd.14038","article-title":"Diagnostic delay in hidradenitis suppurativa is a global problem","volume":"173","author":"Saunte","year":"2015","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref7-bib7","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/exd.14214","article-title":"What causes hidradenitis suppurativa?- 15 years after","volume":"29","author":"Zouboulis","year":"2020","journal-title":"Exp Dermatol"},{"key":"key2023122618012400_ref8-bib8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key2023122618012400_ref9-bib9","article-title":"Interventions for hidradenitis suppurativa","volume":"2015","author":"Ingram","year":"2015","journal-title":"Cochr Datab Syst Rev"},{"key":"key2023122618012400_ref10-bib10","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/jamadermatol.2017.0432","article-title":"Interventions for hidradenitis suppurativa: updated summary of an original Cochrane review","volume":"153","author":"Ingram","year":"2017","journal-title":"JAMA Dermatol"},{"key":"key2023122618012400_ref11-bib11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.17537","article-title":"British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018","volume":"180","author":"Ingram","year":"2019","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref12-bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"key2023122618012400_ref13-bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"key2023122618012400_ref14-bib14","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/bjd.19302","article-title":"What has changed in the UK management of hidradenitis suppurativa from 2014 to 2019?","volume":"183","author":"Hasan","year":"2020","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref15-bib15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bjps.2021.08.038","article-title":"The surgical management of hidradenitis suppurativa in the United Kingdom: a national survey of care pathways informing the THESEUS study","volume":"75","author":"Howes","year":"2022","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"key2023122618012400_ref16-bib16","doi-asserted-by":"crossref","first-page":"BJGPO.2021.0051","DOI":"10.3399\/BJGPO.2021.0051","article-title":"Primary care management of hidradenitis suppurativa: a cross-sectional survey of UK GPs","volume":"5","author":"Collier","year":"2021","journal-title":"BJGP Open"},{"key":"key2023122618012400_ref17-bib17","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/bjd.13163","article-title":"The hidradenitis suppurativa priority setting partnership","volume":"171","author":"Ingram","year":"2014","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref18-bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jaad.2009.12.018","article-title":"Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions","volume":"63","author":"van Der Zee","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"key2023122618012400_ref19-bib19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/bjd.14475","article-title":"Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process","volume":"175","author":"Ingram","year":"2016","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref20-bib20","doi-asserted-by":"crossref","first-page":"e014733","DOI":"10.1136\/bmjopen-2016-014733","article-title":"Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes","volume":"7","author":"Thorlacius","year":"2017","journal-title":"BMJ Open"},{"key":"key2023122618012400_ref21-bib21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/bjd.16093","article-title":"Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II","volume":"178","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref22-bib22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref23-bib23","doi-asserted-by":"crossref","first-page":"e060815","DOI":"10.1136\/bmjopen-2022-060815","article-title":"Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): protocol for a prospective cohort study","volume":"12","author":"Bates","year":"2022","journal-title":"BMJ Open"},{"key":"key2023122618012400_ref24-bib24","volume-title":"Dermatologic Surgery","author":"Hurley","year":"1989"},{"key":"key2023122618012400_ref25-bib25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2340\/00015555-2513","article-title":"Hurley staging refined: a proposal by the Dutch hidradenitis suppurativa expert group","volume":"97","author":"Horv\u00e1th","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"key2023122618012400_ref26-bib26","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bjd.18692","article-title":"The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials","volume":"183","author":"Kirby","year":"2020","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref27-bib27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/bjd.19344","article-title":"Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa","volume":"184","author":"Kirby","year":"2021","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref28-bib28","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Arch Neurol"},{"key":"key2023122618012400_ref29-bib29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"key2023122618012400_ref30-bib30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/bjs.10115","article-title":"Practical guide to the idea, development and exploration stages of the IDEAL framework and recommendations","volume":"103","author":"Pennell","year":"2016","journal-title":"Br J Surg"},{"key":"key2023122618012400_ref31-bib31","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref32-bib32","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref33-bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsp.2013.11.008","article-title":"Generalizability theory: a practical guide to study design, implementation, and interpretation","volume":"52","author":"Briesch","year":"2014","journal-title":"J School Psychol"},{"key":"key2023122618012400_ref34-bib34","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/bjd.20523","article-title":"Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review","volume":"185","author":"Howells","year":"2021","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref35-bib35","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjd.18135","article-title":"A qualitative analysis of psychological distress in hidradenitis suppurativa","volume":"182","author":"Keary","year":"2020","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref36-bib36","volume-title":"Analyzing Qualitative Data","author":"Ritchie","year":"2002"},{"key":"key2023122618012400_ref37-bib37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000496234","article-title":"Development of HiSQOL: a hidradenitis suppurativa-specific quality of life instrument","volume":"5","author":"Thorlacius","year":"2019","journal-title":"Skin Appendage Disord"},{"key":"key2023122618012400_ref38-bib38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1203475416677721","article-title":"Development of a quality-of-life measure for hidradenitis suppurativa","volume":"21","author":"Sisic","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"key2023122618012400_ref39-bib39","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1001\/jamadermatol.2016.1942","article-title":"Exploring coping strategies for patients with hidradenitis suppurativa","volume":"152","author":"Kirby","year":"2016","journal-title":"JAMA Dermatol"},{"key":"key2023122618012400_ref40-bib40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2340\/00015555-1082","article-title":"Psychosocial impact of hidradenitis suppurativa: a qualitative study","volume":"91","author":"Esmann","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"key2023122618012400_ref41-bib41","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/bjd.18818","article-title":"Identifying barriers to care and research in hidradenitis suppurativa: findings from a patient engagement event","volume":"182","author":"Shukla","year":"2020","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref42-bib42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00403-019-02027-3","article-title":"Hidradenitis suppurativa on Facebook: thematic and content analyses of patient support group","volume":"312","author":"Fisher","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"key2023122618012400_ref43-bib43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09546634.2017.1341614","article-title":"Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa","volume":"29","author":"Kimball","year":"2018","journal-title":"J Dermatol Treat"},{"key":"key2023122618012400_ref44-bib44","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(09)61116-8","article-title":"No surgical innovation without evaluation: the IDEAL recommendations","volume":"374","author":"McCulloch","year":"2009","journal-title":"Lancet"},{"key":"key2023122618012400_ref45-bib45","volume-title":"Funding opportunities","author":"NIHR"},{"key":"key2023122618012400_ref46-bib46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1369-7625.2004.00278.x","article-title":"What does it mean to involve consumers successfully in NHS research? A consensus study","volume":"7","author":"Telford","year":"2004","journal-title":"Health Expect"},{"key":"key2023122618012400_ref47-bib47","volume-title":"Involve patients","author":"NIHR"},{"key":"key2023122618012400_ref48-bib48","first-page":"i","article-title":"Consensus development methods, and their use in clinical guideline development","volume":"2","author":"Murphy","year":"1998","journal-title":"HTA"},{"key":"key2023122618012400_ref49-bib49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/bjd\/ljad152","article-title":"Research priorities in the management of hidradenitis suppurativa","volume":"189","author":"Leighton","year":"2023","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref50-bib50","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljad388","article-title":"Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort study","author":"Ingram","year":"2023","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref51-bib51","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"key2023122618012400_ref52-bib52","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2020.12.089","article-title":"The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study","volume":"85","author":"van Straalen","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"key2023122618012400_ref53-bib53","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1524-4725.2009.01214.x","article-title":"Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser","volume":"35","author":"Tierney","year":"2009","journal-title":"Dermatol Surg"},{"key":"key2023122618012400_ref54-bib54","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/PRS.0b013e31821e6fb5","article-title":"Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study","volume":"128","author":"Highton","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"key2023122618012400_ref55-bib55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2020.04.117","article-title":"Treatment of hidradenitis suppurativa using a long-pulsed hair removal neodymium:yttrium-aluminium\u2013garnet laser: a multicenter, prospective, randomized, intraindividual, comparative trial","volume":"84","author":"Naouri","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"key2023122618012400_ref56-bib56","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1684\/ejd.2020.3920","article-title":"Intense pulsed light treatment for hidradenitis suppurativa: a within-person randomized controlled trial","volume":"30","author":"Andersen","year":"2020","journal-title":"Eur J Dermatol"},{"key":"key2023122618012400_ref57-bib57","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1159\/000518540","article-title":"LAight\u00ae therapy significantly enhances treatment efficacy of 16 weeks of topical clindamycin solution in Hurley I and II hidradenitis suppurativa: results from period A of RELIEVE, a multicenter randomized, controlled trial","volume":"238","author":"Schultheis","year":"2022","journal-title":"Dermatology"},{"key":"key2023122618012400_ref58-bib58","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ajd.13600","article-title":"Ultrasound-guided de-roofing of epithelialised tunnels of hidradenitis suppurativa","volume":"62","author":"Der Sarkissian","year":"2021","journal-title":"Australas J Dermatol"},{"key":"key2023122618012400_ref59-bib59","first-page":"235","article-title":"A comparison of skin grafting and healing by granulation, following axillary excision for hidradenitis suppurativa","volume":"65","author":"Morgan","year":"1983","journal-title":"Ann R Coll Surg Engl"},{"key":"key2023122618012400_ref60-bib60","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bjd.21821","article-title":"Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa","volume":"187","author":"Hasan","year":"2022","journal-title":"Br J Dermatol"},{"key":"key2023122618012400_ref61-bib61","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"key2023122618012400_ref62-bib62","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","article-title":"Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial","volume":"82","author":"Casseres","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"key2023122618012400_ref63-bib63","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"key2023122618012400_ref64-bib64","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/jdv.18163","article-title":"Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US","volume":"36","author":"Ingram","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key2023122618012400_ref65-bib65","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jamadermatol.2021.4741","article-title":"Patient impressions and outcomes after clinic-based hidradenitis suppurativa surgery","volume":"158","author":"Ravi","year":"2022","journal-title":"JAMA Dermatol"},{"key":"key2023122618012400_ref66-bib66","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surg"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2044523","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/HWNM2189\/HWNM2189.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2044523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T12:34:01Z","timestamp":1703594041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/HWNM2189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":66,"alternative-id":["10.3310\/HWNM2189"],"URL":"https:\/\/doi.org\/10.3310\/hwnm2189","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"04-2019","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"10-2022","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"03-2023","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}